

INVESTOR BRIEFING ON EXO-OC TEST AND STUDY OUTCOME

Melbourne, Australia, 8 July 2026: INOVIQ Limited (ASX:IIQ) (INOVIQ or the **Company**) advises that, following the announcement released on 1 July 2026 regarding the outcome of the retrospective clinical study of its EXO-OC™ ovarian cancer test, the Company will host an online Investor Briefing to discuss the study outcome, key findings from the retrospective study, the actions being taken to advance development of EXO-OC™ and the pathway to commercialisation, followed by an investor Q&A.

The Board and Management acknowledge the disappointing outcome of the retrospective study and have commenced a comprehensive technical review to strengthen the design and execution of future studies, minimise any impact on development timelines, and support the path to commercialisation and long-term shareholder value creation.

INOVIQ Chairman Peter Gunzburg said: *"Whilst the study outcome was disappointing it does not detract from the potential of our EXO-OC™ test. What is evident, amongst other things, is the difficulty in obtaining sufficient number of suitably robust samples."*

INOVIQ remains committed to commercialising the EXO-OC™ test, initially as a LDT in the US for early detection of ovarian cancer, before further developing the test as an IVD for screening of ovarian cancer.

Webinar agenda

- Retrospective clinical study outcomes;
- EXO-OC test and algorithm refinement;
- Ongoing development and commercialisations plans; and
- Summary and Q&A

Webinar details

Date: Tuesday, 14 July 2026

Time: 11:00am AEST

Registration: https://us06web.zoom.us/webinar/register/WN_jb_a_OxTp6sry8N66UpFw

After registering, participants will receive a confirmation email containing details on how to join the webinar. A recording of the briefing will also be made available on the INOVIQ website following the event at [click here](#).

Authorised for release by the INOVIQ Limited Board of Directors.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Peter Gunzburg
Chairman
E peter.gunzburg@gmail.com
M +61 412 927 773

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.